Relmada’s Phase III Depression Study Scuppered By ‘Placebo Paradox’
Adjunctive Studies Will Continue
An unexpectedly strong response in the placebo arm has derailed a monotherapy study of Relmada’s investigational antidepressant REL-1017, but the company will continue its trials as an adjunctive therapy.
You may also be interested in...
With a pair of Phase III setbacks due to high placebo response, Relmada reports positive efficacy and safety data from an open-label trial while awaiting data from two ongoing pivotal studies for REL-1017, an NMDA antagonist.
After a year-long delay, Axsome gets US FDA approval of bupropion/dextromethorphan combo with broad label for major depression. Firm expects to launch in Q4 with pricing intended for broad patient access.
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.